Pharmaceuticals

BioScience Today – Patenting aerospace medicines

Patenting aerospace medicines – the final frontier? Consulting Attorney, Julie Barrett-Major recently wrote for BioScience Today on the subject of Patenting aerospace medicines. You can find Julie’s article below, or read the full magazine here.      Should you wish to discuss this topic, please contact the author, Julie Barrett-Major, or your usual AA… Read more »

Landmark UK Supreme Court Judgment in Warner Lambert v Generics (Mylan) & Actavis (Pregabalin/Lyrica)

Sufficiency and Infringement of Second Medical Use Patents Landmark UK Supreme Court Judgment in Warner Lambert v Generics (Mylan) & Actavis (Pregabalin/Lyrica)   The Supreme Court of the United Kingdom has now released their long-awaited decision relating to the tests for sufficiency and infringement for second medical use patents, in particular those with so-called “Swiss-form”… Read more »

Mike Jennings attends EPO’s AI Conference

Commenting on the EPO’s AI discussions Partner Mike Jennings attended the EPO’s AI conference on 30 May, commenting:  “The EPO deserves praise for investing in an excellent discussion with industry and members of the judiciary about the future for AI patenting. The 30 May 2018 conference was part of that discussion. The consultation provided a good… Read more »

Patenting computer-implemented inventions in the era of AI

Mike Jennings speaks at the London IP Summit on “Patenting computer-implemented inventions in the era of AI”   Partner Mike Jennings spoke at the London IP Summit on the 16 October 2018 on the topic “Patenting computer-implemented inventions in the era of AI”. Mike spoke alongside representatives from IBM, Nokia, AT&T, ARM Holdings plc, NXP Semiconductors,… Read more »

AA Thornton to attend New Delhi events this November

The World IP Forum and APAA Conference, New Delhi, November 2018 Patent attorneys Julie Barrett-Major and Leonita Paulraj will be in New Delhi from 14 – 21 November, where they will attend the World IP Forum and APAA conferences. Whilst in New Delhi, Julie and Leonita will also attend the World IP Forum during 14-16 November…. Read more »

PTMG Autumn Conference 2018

AA Thornton returns to PTMG in Dubrovnik! Consulting Patent Attorney Julie Barrett-Major  and Trade Mark Attorney Suzanne Power represented the firm at the Autumn Pharmaceutical Trade Marks Group (PTMG) conference in Dubrovnik, Croatia from 3rd to 6th October 2018. Julie and Susie hosted a tea and round table event at the Hotel Croatia Cavtat just before the start of… Read more »

Protection for cannabis-based IP

Protection for cannabis-based IP in the wake of announcement of impending legalisation of medicinal cannabis   The legalisation of medicinal and recreational cannabis in several US states, Canada and some European countries has resulted in a new economic market rising from what was previously an illegal trade. Meanwhile, in the UK, the recent cases of… Read more »

EU: Falsified Medicines Directive: Implications for parallel importers and of Brexit

EU: Falsified Medicines Directive: Implications for parallel importers and of Brexit This article was updated: 8 October 2018   Introduction to the Falsified Medicines Directive Directive 2011/62/EU, better known as “The Falsified Medicines Directive” or “FMD”, came into force on 2 January 2013, with the aim of preventing falsified medicines from entering the legitimate supply… Read more »

WIPO Magazine has announced the launch of a new tool linking patents and drugs: Pat-INFORMED

WIPO Magazine has announced[1] the launch of a new tool linking patents and drugs: Pat-INFORMED The concept The World Intellectual Property Organization (WIPO) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with 20 participating global pharmaceutical companies, have joined forces to globalise the concept of the US’s ‘Orange Book’. Most drugs have… Read more »

Assessment of “plausibility” requirement from the EPO perspective

Assessment of “plausibility” requirement from the EPO perspective Introduction This article considers how the EPO views the requirement of “plausibility”, which can arise during both the assessment of “sufficient disclosure” of the invention and “inventive step” in proceedings before the EPO, particularly in relation to inventions in the Pharmaceuticals and Life Sciences field. The EPO… Read more »

Categories

Archives